Factors that influence treatment selection in patients with persistent or recurrent MTC are the nature of the symptoms, sites of the disease, burden of disease, levels of serum Ctn and CEA, and rate of progression of structural disease [35]. Here, CEACAM5 is linked to medullary thyroid gland carcinoma.